Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05905003 · ClinicalTrials.gov registry record
AMP SCZ® Observational Study: PREDICT-DPACC
A clinical trial of Psychosis and Clinical High-Risk, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 2,617
- Enrollment target
- 20
- Study locations
NCT05905003: Active study of Psychosis and Clinical High-Risk, sponsored by Brigham and Women's Hospital.
NCT05905003 is a study of Psychosis and Clinical High-Risk that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 2,617 participants, above the 104-participant average among 35 other Psychosis trials with a reported enrollment target (2416% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05905003, a study of Psychosis and Clinical High-Risk, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 2,617 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that can be used to predict the trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the testing of pharmacological interventions for CHR individuals in need. The goal is to accurately predict which individuals are likely to remit, experience an acute psychotic episode, or have intermediate outcomes that feature persistent attenuated psychotic and/or mood symptoms along with functional impairment. The prediction algorithms will have the potential to serve as early indicators of treatment efficacy in CHR persons. The AMP SCZ research program is made up of the Psychosis Risk Evaluation, Data Integration, and Computational Technologies - Data Processing, Analysis and Coordination Center (PREDICT-DPACC) and two clinical research networks, the Psychosis-Risk Outcomes Network (ProNET) and the Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT) networks. The two clinical research networks will recruit a large cohort of CHR young people aged 12-30 years (n=1,977) and healthy control (HC) participants (n=640) across 42 participating investigative sites from 13 countries. CHR participants will complete screening, baseline assessments and a battery of follow-up assessments across 18 - 24 months. HC participants will complete screening and baseline assessments and a subset (5 per site) will complete month 2, 12 and 24 visits.
Primary Outcome
Conversion to psychosis as defined by psychosis threshold criteria on the PSYCHS.
Conditions Studied
Study Locations (20)
California
- University of California Irvine - Irvine
- University of California Los Angeles - Los Angeles
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
Pennsylvania
- University of Pennsylvania - Philadelphia
- Temple University - Philadelphia
- University of Pittsburgh - Pittsburgh
Connecticut
- Hartford Healthcare - Hartford
- Yale University/Connecticut Mental Health Center - New Haven
New York
- Icahn School of Medicine at Mount Sinai - New York
- Northwell Health - Queens
Victoria
- Headspace, Craigieburn - Craigieburn
- Headspace, Glenroy - Glenroy
Georgia
- University of Georgia - Athens
Illinois
- Northwestern University - Evanston
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,617 participants |
| Start Date | 2022-06-02 |
| Est. Completion | 2027-04-30 |
What the registry record for NCT05905003 still lists
NCT05905003 is an observational study that tracks outcomes without assigning an intervention. Its 2,617 participants enrollment target places it among the larger protocols in the corpus, above the 104-participant average among 35 other Psychosis trials with a reported enrollment target (2416% higher).
The record links to 4 conditions, with Psychosis appearing as the primary indexed condition, and to 0 interventions.
NCT05905003 names 20 study sites across 12 states, led by California, Pennsylvania, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05905003 about?
NCT05905003 is a clinical study titled "AMP SCZ® Observational Study: PREDICT-DPACC". The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that can be used to predict the trajectories and outcomes of individuals at ...
What is the current status of trial NCT05905003?
This trial is currently active not recruiting. The enrollment target is 2,617 participants. The study started on 2022-06-02. Estimated completion is 2027-04-30.
What conditions does trial NCT05905003 study?
This clinical trial studies the following conditions: Psychosis, Clinical High-Risk, Remission, Conversion.
Who is sponsoring clinical trial NCT05905003?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05905003 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05905003's enrollment target sits among peer trials
2,617 1st of 35 higher than 35 of 35 other Psychosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Determining the Role of Social Reward Learning in Social Anhedonia
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
RECRUITING · NA
-
Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care
RECRUITING · NA
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI